CO5180625A1 - 1,2,4,5-tetrahidro-benzo[d]azepinas - Google Patents

1,2,4,5-tetrahidro-benzo[d]azepinas

Info

Publication number
CO5180625A1
CO5180625A1 CO00058410A CO00058410A CO5180625A1 CO 5180625 A1 CO5180625 A1 CO 5180625A1 CO 00058410 A CO00058410 A CO 00058410A CO 00058410 A CO00058410 A CO 00058410A CO 5180625 A1 CO5180625 A1 CO 5180625A1
Authority
CO
Colombia
Prior art keywords
chr
lower alkyl
ncf3
cycloalkyl
nitro
Prior art date
Application number
CO00058410A
Other languages
English (en)
Inventor
Adam Geo
Alfred Binggeli
Hans-Peter Marki
Vincent Mutel
Maurice Wilhelm
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5180625A1 publication Critical patent/CO5180625A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a derivados de 1,2,4,5-tetrahidro-benzo[d]azepin de la fórmula general <EMI FILE="00058410_1" ID="1" IMF=JPEG >En dondeR1 significa hidrógeno, alquilo inferior, oxígeno, halógeno, ó -OR, -O(C3-C6)cicloalquilo, -O(CHR)n-(C3-C6)cicloalquilo, -O(CHR)nCN, -O(CHR)nCF3, -O(CHR)(CHR)nNR2, -O(CHR) -(CHR)nOR, -O(CHR)n-alquenilo inferior, -OCF3, -OCF2-R, OCF2-alquenilo inferior, -OCHRF, -OCHF-alquenilo inferior, -OCF2CRF2, -OCF2Br, -O(CHR)nCF2Br -O(CHR)n-fenilo, en donde el grupo fenilo opcionalmente se puede substituir independientemente uno del otro por entre uno y tres grupos alquilo inferior, alcoxi inferior, halógeno, nitro o ciano, -O(CHR)(CHR)n-morfolino, -O(CHR)(CHR)n-pirrolidino, -O(CHR)(CHR)n-piperidino, -O(CHR)(CHR)n-imidazol, -O(CHR)(CHR)n-triazol, -O(CHR)n-piridino,-O(CHR)(CHR)n-Osi-alquilo inferior,-O(CHR)(CHR)nOS(O)2-alquilo inferior, -O(CH2)nCH=CF2, -O(CHR)n-2,2-dimetil-[1,3]dioxo-Iano, -O(CHR)n-CHOR-CH2OR, -O(CHR)n-CHOR-(CHR)n-CH2 OR o -SR o S(CHR)nCOOR, ó -NR2, -N(R)(CHR) (CHR)nOR, -N(R)(CHR)nCF3, -N(R)(CHR)(CHR)n-morfolino, -N(R)(CHR)(CHR)n-imidazol, -N(R)(CHR)(CHR)n-pirrolidino, -N(R)(CHR)(CHR)n-pirrolidin-2-ona, -N(R)(CHR)(CHR)n-piperidino, -N(R)(CHR)(CHR)n-triazol, -N(R)(CHR)n-piridino, n es 1- 6; R significa hidrógeno, alquilo inferior o alquenilo inferior, independientemente uno de otro, en el caso de que haya más de un grupo R;R2 significa nitro o ciano;R3 significa hidrógeno, alquilo inferior, =O, =S, -SR, -S(O)2-alquilo inferior, -(C3-C6)cicloalquilo o piperazino, substituido opcionalmente por alquilo inferior, o -CONR2, -(CHR)nCONR2, -(CHR)nOR, -(CH2)n-CF3, -CF3, -(CHR)nOC(O)CF3, -(CHR)nCOOR, -(CHR)nSC6H5, en donde grupo fenilo opcionalmente puede estar substituido independientemente uno de otro por entre uno y tres grupos alquilo inferior, alcoxi inferior, halógeno, nitro o ciano, -(CHR)n-1,3-dioxo-1,3-dihidro-isoindol,-(CHR)n-tetrahidro-piran-2-iloxi o -(CHR)n-S-alquilo inferior, o -NR2, NRCO-alquilo inferior, -NRCHO,-N(R)(CHR)nCN, -N(R)(CHR)nCF3, -N(R)(CHR)(CHR)n-OR, ...
CO00058410A 1999-08-06 2000-08-03 1,2,4,5-tetrahidro-benzo[d]azepinas CO5180625A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115557 1999-08-06

Publications (1)

Publication Number Publication Date
CO5180625A1 true CO5180625A1 (es) 2002-07-30

Family

ID=8238742

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00058410A CO5180625A1 (es) 1999-08-06 2000-08-03 1,2,4,5-tetrahidro-benzo[d]azepinas

Country Status (27)

Country Link
US (1) US6218385B1 (es)
JP (1) JP3260350B2 (es)
KR (1) KR100390116B1 (es)
CN (1) CN1146455C (es)
AR (1) AR025035A1 (es)
AT (1) ATE254614T1 (es)
AU (1) AU774485B2 (es)
BR (1) BR0003375A (es)
CA (1) CA2314798A1 (es)
CO (1) CO5180625A1 (es)
DE (1) DE60006618T2 (es)
ES (1) ES2209728T3 (es)
HR (1) HRP20000520A2 (es)
HU (1) HUP0003112A3 (es)
ID (1) ID26743A (es)
IL (1) IL137688A0 (es)
MA (1) MA26748A1 (es)
NO (1) NO20003966L (es)
NZ (1) NZ506096A (es)
PE (1) PE20010467A1 (es)
PL (1) PL341890A1 (es)
RU (1) RU2240317C2 (es)
SG (1) SG93251A1 (es)
TR (1) TR200002298A2 (es)
UY (1) UY26276A1 (es)
YU (1) YU49700A (es)
ZA (1) ZA200003927B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4077319B2 (ja) * 2000-12-22 2008-04-16 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ１アンタゴニストとしてのテトラヒドロ−（ベンゾ又はチエノ）−アゼピン−ピラジン及びトリアジン誘導体
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
ES2401216T3 (es) * 2002-12-20 2013-04-17 Glaxo Group Limited Nuevos derivados de benzazepina
EP2332920A3 (en) * 2003-06-17 2011-12-21 Arena Pharmaceuticals, Inc. Processes for preparing 3-benzazepines
PL2332921T3 (pl) * 2003-06-17 2016-08-31 Arena Pharm Inc Chlorowodorek 8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
US20070275949A1 (en) * 2003-10-22 2007-11-29 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
NZ555981A (en) 2004-12-21 2011-01-28 Arena Pharm Inc Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
NZ555482A (en) 2004-12-23 2011-01-28 Arena Pharm Inc Compositions comprising a 5HT2C receptor modulator and 2-methylamphetamine and methods of use
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2471779A1 (en) 2006-04-03 2012-07-04 Arena Pharmaceuticals, Inc. Process for the resolution of a mixture of (R)- and (S)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008066750A1 (en) 2006-11-22 2008-06-05 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
ES2522587T3 (es) * 2006-12-05 2014-11-17 Arena Pharmaceuticals, Inc. Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2009111004A1 (en) 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8952197B2 (en) 2009-06-18 2015-02-10 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
CN103347523A (zh) 2010-09-01 2013-10-09 艾尼纳制药公司 向具有肾损伤的个体给药氯卡色林
CA2808909A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
WO2012030957A2 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
BR112015007779A2 (pt) 2012-10-09 2017-07-04 Arena Pharm Inc célula de fluxo de permeabilidade e sistema de condutância hidráulica

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206210A (en) * 1977-01-19 1980-06-03 Smithkline Corporation Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
SK400992A3 (en) * 1990-11-06 1995-08-09 Pfizer Quinazolines derivatives for enhancing antitumor activity
US5241065A (en) * 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity

Also Published As

Publication number Publication date
CN1283623A (zh) 2001-02-14
UY26276A1 (es) 2000-10-31
ID26743A (id) 2001-02-08
ES2209728T3 (es) 2004-07-01
PL341890A1 (en) 2001-02-12
HUP0003112A3 (en) 2003-07-28
RU2240317C2 (ru) 2004-11-20
PE20010467A1 (es) 2001-04-17
SG93251A1 (en) 2002-12-17
HU0003112D0 (en) 2000-10-28
TR200002298A3 (tr) 2001-03-21
NZ506096A (en) 2002-08-28
US6218385B1 (en) 2001-04-17
AU774485B2 (en) 2004-07-01
HRP20000520A2 (en) 2001-06-30
NO20003966L (no) 2001-02-07
AU4897900A (en) 2001-02-08
IL137688A0 (en) 2001-10-31
JP2001089472A (ja) 2001-04-03
TR200002298A2 (tr) 2001-03-21
JP3260350B2 (ja) 2002-02-25
CN1146455C (zh) 2004-04-21
DE60006618D1 (de) 2003-12-24
ATE254614T1 (de) 2003-12-15
NO20003966D0 (no) 2000-08-04
KR20010082510A (ko) 2001-08-30
ZA200003927B (en) 2001-02-06
YU49700A (sh) 2003-04-30
KR100390116B1 (ko) 2003-07-04
BR0003375A (pt) 2001-03-13
DE60006618T2 (de) 2004-09-23
HUP0003112A2 (hu) 2002-11-28
AR025035A1 (es) 2002-11-06
CA2314798A1 (en) 2001-02-06
MA26748A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
CO5180625A1 (es) 1,2,4,5-tetrahidro-benzo[d]azepinas
PE20021002A1 (es) Compuestos heterociclicos condensados
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
MY140012A (en) Heterocylic substituted phenyl methanones
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
CO5090835A1 (es) Biciclo [2.2.1] heptanos y compuestos relacionados
PT89020A (pt) Processo para a preparacao de 3-(4(1-substituidas-4-piperazinil)butil)-4-tiazolidinonas e de composicoes farmaceuticas que as contem
ES2186017T3 (es) Procedimientos para la preparacion de delta 4,5-esteroides 3-ceto-7alfa-alcoxicarbonil-sustituidos y compuestos intermedios de utilidad en los mismos.
PE20001088A1 (es) Compuestos derivados de tetrahidrobenzazepina
CO5160347A1 (es) Derivados de acido carbamico
FI120306B (fi) Menetelmä uusien 5-HT1A-antagonististen 2,3-dihydro-1,4-bentsodioksin-5-yylipiperatsiinijohdannaisten valmistamiseksi
ES2086326T3 (es) Metodo para intensificar la quimiluminiscencia.
NZ511584A (en) Benzoxazole substituted piperazine and piperidine derivatives useful for treating central nervous disorders, depression and anxiety
AR039122A1 (es) Derivados de ftalimido como inhibidores de monoamino oxidasa b
CO5251384A1 (es) Derivados de piperazina sustituidos, su preparacion y su empleo como medicamentos
RU95122287A (ru) Производные нипекотиновой кислоты как вещества, препятствующие тромбообразованию
AR064137A1 (es) Derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona,antagonistas de receptores de vasopresina v1a,metodo de obtencion,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos coronarios,depresivos y otras enfe
AR032379A1 (es) Derivados de 1,2,4,5-tetrahidro-benzo(d)azepina-pirazina y triazina y derivados de 1,2,4,5-tetrahidro-tieno(d)azepina-pirazina y triazina
ATE146479T1 (de) Modifizierte oligodeoxyribonukleotide, ihre herstellung und ihre therapeutische verwendung
PE20020687A1 (es) Imidazoles y tiazoles sustituidos como inhibidores de la farnesil transferasa
AR043964A1 (es) Derivados de 4- ( 2-fenilsulfanil-fenil) 1,2,3,6-tetrahidropiridina como anhibidores de la recaptacion de serotonina
AR064135A1 (es) Derivados de espiro -piperidina
ECSP003604A (es) 1, 2, 4, 5- tetrahidro- benzo[d] azepinos
FI873009A (fi) Foerfarande foer framstaellning av (2-dimetylaminoetyl)-/2-/(2-tiometylfenyl)-(fenylmetyl)/amino-2-oxoetyl /karbamater eller -karbamider.
SG164268A1 (en) Quinolin-4-yl derivatives i

Legal Events

Date Code Title Description
FD Application lapsed